Can We Miss Pigmented Lesions in Psoriasis Patients?

Exclusion Criteria

• •1. Serum creatinine \> 3.0 mg/dL (265 micromoles/L)
• •2. Serum potassium \< 3.5 mmol/L or \> 5.5 mmol/L
• •3. Serum alanine aminotransferase or Aspartate transaminase \> 3 times the upper limit of normal for the Lab
• •4. Platelet count \< 100,000/mm3
• •5. White blood cell count \< 3,000 cells/mm3
• •6. Hemoglobin, hematocrit, or red blood cell count outside 30% of the upper or lower limits of normal for the Lab
• •7. Systemic therapy use (e.g. phototherapy, methotrexate, cyclosporine, oral steroids, systemic biologics) within the previous 4 weeks
• •8. Topical therapy use (e.g. topical steroids, vitamin D derivatives) within the previous 2 weeks
• •9. Subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit.
• •10. Subjects who have known hypersensitivity to Enbrel or any of its components or who is known to have antibodies to etanercept
• •11. Prior or concurrent cyclophosphamide therapy
• •12. Concurrent sulfasalazine therapy
• •13. Known Human immunodeficiency virus-positive status or known history of any other immunosuppressing disease
• •14. Active severe infections within 4 weeks before screening visit, or between the screening and baseline visits
• •15. Untreated Lyme disease
• •16. Severe comorbidities (diabetes mellitus requiring insulin, CHF of any severity, MI, CVA or TIA within 3 months of screening visit, unstable angina pectoris, uncontrolled hypertension (sitting systolic BP \<80 mm Hg or \> 160 or diastolic BP \> 100 mm Hg), oxygen-dependent severe pulmonary disease, history of cancer within 5 years \[other than resected cutaneous basal or squamous cell carcinoma or in situ cervical cancer\])
• •17. History of TB or TB exposure, chronic hepatitis B or hepatitis C, SLE, history of multiple sclerosis, transverse myelitis, optic neuritis or epilepsy
• •18. History of recent alcohol or substance abuse (\< 1 year)
• •19. Pregnant or lactating females
• •20. Use of a live vaccine 90 days prior to, or during this study
• •21. Any condition judged by the patient's physician to cause this clinical trial to be detrimental to the patient
• •22. History of non-compliance with other therapies